MedPath

Tagged News

Veeda Lifesciences Partners with Mango Sciences to Deploy AI-Powered Platform for Enhanced Clinical Trial Diversity

AIOncology
  • Veeda Lifesciences has announced an investment in Boston-based Mango Sciences to leverage AI capabilities for enhancing clinical trial speed, efficiency, and quality across its global network.
  • The partnership will deploy Mango Sciences' AI-powered Querent platform to automate patient identification with precision and expand reach across Europe, particularly focusing on oncology drug development.
  • The collaboration aims to improve diversity in clinical trials through broader representation of non-Caucasian populations, meeting regulatory expectations and pharmaceutical company demands.
  • The integration of Large Language Models and Generative-AI into the Querent platform will drive operational efficiencies and improve real-world evidence for better patient-drug matching.

Biorce Secures €5M to Transform Clinical Trials with AI-Driven Platform

AIOncology
  • Barcelona-based healthtech startup Biorce raised €5 million from Norrsken VC to scale its AI-driven platform that addresses clinical trial inefficiencies.
  • The company's Jarvis platform aims to reduce the 70% of clinical trials that face startup delays and 60% that require costly amendments averaging $250K-$450K each.
  • Biorce's AI technology has already streamlined over 300 clinical trial protocols across oncology and neurology, with potential to unlock $13-25 billion in industry value.
  • The funding will support US market expansion, team growth, and product development as the clinical trial market grows from $84 billion in 2024 to $150 billion by 2034.

HeartBeat.bio and biotx.ai Partner to Accelerate Heart Failure Drug Discovery Using AI and Human Cardiac Organoids

AIDrug DiscoveryPrecision Medicine
  • HeartBeat.bio and biotx.ai have formed a strategic partnership to identify and validate novel therapeutic targets for heart failure using AI-driven genetics and human cardiac organoid models.
  • The collaboration combines biotx.ai's Mendelian randomization platform with HeartBeat.bio's Cardioid Drug Discovery Platform to discover genetically validated targets and test them in human-relevant systems.
  • Heart failure affects over 30 million people globally, and despite recent therapeutic advances, many patients lack effective treatment options targeting underlying disease mechanisms.
  • The partnership aims to unlock a new generation of precision medicines for heart failure by focusing on cardiomyopathies, myocardial fibrosis, and chronic cardiac remodeling.

Synfini Secures $8.9 Million to Accelerate AI-Driven Small Molecule Drug Discovery Platform

AIDrug Discovery
  • Synfini raised $8.9 million in additional funding led by JSL Health Capital, bringing total funding to $53 million to advance its AI Cloud Foundry platform for small molecule drug discovery.
  • The company's integrated platform combines artificial intelligence, automated synthesis, and iterative molecular design to reduce small molecule iteration cycles from months to days.
  • Synfini plans to use the funding to expand its software and automated lab capabilities, hire scientific and engineering talent, and grow commercial partnerships in GPCR-targeted therapeutics and precision oncology.
  • The AI-driven chemistry automation platform eliminates traditional bottlenecks by streamlining target selection, compound design, and synthesis into a unified workflow.

Chugai and Gero Form $250M Partnership to Develop AI-Driven Antibody Therapies for Age-Related Diseases

AIMonoclonal AntibodyDrug Discovery
  • Chugai Pharmaceutical and Singapore-based Gero have entered into a joint research and license agreement to develop novel antibody therapies targeting age-related diseases using AI-driven drug discovery.
  • The collaboration combines Gero's physics-based machine learning platform for target identification with Chugai's proprietary antibody engineering technologies to create first-in-class therapeutics.
  • Under the agreement, Chugai will pay up to approximately $250 million in milestone payments plus royalties, while gaining exclusive worldwide rights to develop and commercialize antibodies for Gero-identified targets.
  • The partnership represents a strategic move by Chugai to accelerate innovation through open collaboration as part of its TOP I 2030 growth strategy focused on global first-class drug discovery.

Everest Medicines Advances AI-Powered mRNA Platform with Cancer Vaccine Breakthroughs

Drug ApprovalCAR-TAI
  • Everest Medicines unveiled major breakthroughs in its proprietary AI-powered mRNA platform during its 2025 R&D Day, showcasing a fully integrated system spanning antigen design to manufacturing.
  • The company's personalized cancer vaccine EVM16 demonstrated robust immunogenicity and mutation-specific T-cell responses in early clinical trials, while off-the-shelf vaccine EVM14 received FDA IND clearance.
  • Everest's innovative in vivo CAR-T program achieved high T-cell transduction efficiency and effective B-cell clearance in preclinical studies, offering a scalable alternative to conventional CAR-T therapies.
  • The company is pursuing global partnerships with top 20 pharmaceutical companies to accelerate international deployment of its clinically validated mRNA assets.

Lunit Partners with Microsoft to Develop AI-Powered Cancer Diagnostic Tools on Azure Platform

AI
  • Lunit, a leading AI cancer diagnostics company, has announced a collaboration with Microsoft to accelerate the delivery of AI-powered healthcare solutions through Microsoft Azure's cloud infrastructure.
  • The partnership will focus on developing AI model customization services that allow fine-tuning using site-specific clinical data to address cross-site performance variability challenges in real-world clinical environments.
  • Lunit plans to leverage Microsoft's agentic AI frameworks to create end-to-end workflow automation tools that simplify clinical decision-making and enhance operational efficiency across cancer care.
  • The collaboration aims to expand access to Lunit's AI diagnostic tools, including SCOPE HER2 for colorectal cancer and INSIGHT DBT for breast cancer detection, particularly in the U.S. market.

Monte Rosa's AI-Powered Discovery Engine Expands Molecular Glue Degrader Target Space in Science Publication

AIDrug Discovery
  • Monte Rosa Therapeutics published groundbreaking research on the cover of Science magazine, demonstrating how their AI and machine learning technologies have dramatically expanded the targetable protein space for molecular glue degraders.
  • The company's proprietary QuEEN discovery engine identified over 100 classes of proteins previously considered undruggable, spanning diverse therapeutic areas including immunology, inflammation, and oncology.
  • The research reveals new rules governing cereblon-based protein degradation, enabling rational design of highly selective degrader therapies for historically intractable therapeutic targets.

Ebenbuild Secures €2.3 Million EIC Grant to Advance Digital Twin Platform for Respiratory Drug Development

AI
  • Ebenbuild received €2.3 million from the European Innovation Council Accelerator program to advance its AI-enabled digital twin platform for lung simulation and respiratory drug development.
  • The funding supports the market launch of Twinhale, the first scalable in silico trial software for pulmonary drug delivery that enables patient-specific predictions of drug deposition in lungs.
  • Validation studies demonstrate Twinhale's unprecedented accuracy in predicting local drug deposition, outperforming existing models and enabling design decisions typically inaccessible through traditional testing methods.
  • The company targets the rapidly growing €5 billion in silico trials market and aims to expand into clinical decision support systems and personalized medicine markets valued at over €300 billion by 2030.

Auriga Research Partners with San Francisco Research Institute to Advance AI-Driven Clinical Research Across Global Markets

AI
  • Delhi-based Contract Research Organization Auriga Research has entered into a strategic partnership with San Francisco Research Institute to strengthen global clinical research and promote AI-integrated healthcare solutions across India, the United States, and Africa.
  • The collaboration will focus on joint clinical trials using AI for patient recruitment, monitoring, and analytics, with Auriga leading clinical operations in India and SFRI driving market expansion in the US, Japan, and Europe.
  • SFRI will support regulatory strategy and commercial partnerships, including product registration with national health agencies and connecting Auriga to distributors in markets such as Nigeria and the US.
  • Both organizations will jointly expand their Research Training Program and co-develop new products and AI applications for healthcare while pursuing government and foundation-funded projects.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.